GlassScriptPhysician profile
Mario A Sabates
NPI 1740330984
$3,820.78
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $294 · 2021: $565 · 2022: $591 · 2023: $183 · 2024: $788 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $962.68 | 2019-2025 | Clareon, Lensx, Simbrinza |
| Abbvie INC. | $559.70 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $398.19 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $396.44 | 2019-2021 | |
| Glaukos Corporation | $184.15 | 2024 | Idose |
| Allergan, INC. | $174.70 | 2019-2022 | |
| Biotissue Holdings INC. | $172.46 | 2021-2022 | |
| Shire North American Group INC | $145.23 | 2019 | |
| Ocular Therapeutix, INC. | $143.52 | 2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $129.48 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $129.41 | 2022-2025 | Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $124.67 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $84.42 | 2019-2020 | |
| Thea Pharma INC. | $69.73 | 2024-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $47.88 | 2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.66 | 2024 | Tepezza |
| Akorn, INC. | $14.56 | 2020 | |
| Sight Sciences, INC. | $14.29 | 2022 | |
| Amarin Pharma, INC. | $14.27 | 2020 | |
| Astellas Pharma US INC | $13.34 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Sabates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.